本帖最后由 老马 于 2012-1-13 21:20 编辑
1 x% ^$ w) e" ^& Q& a; N. r) L c8 Y+ H6 Z" Y, z: {! @
爱必妥和阿瓦斯丁的比较9 n4 o& S' \( K8 N, `7 m
0 I7 p+ h" e& i6 _ o9 H+ @/ w
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
6 L0 i. f! T2 i: m
; ]( Z: v/ o4 r R
5 [) V) N. \' L* y: U, V; Vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 @) P& a2 e6 ^; E! u
================================================== R! \: {0 k; H
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)8 d/ L6 Y0 G: }3 L+ T) G
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: V. ~& K5 A( ~0 ?( `Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 m8 d+ f5 C) f/ ]2 `
|